Edwards Lifesciences — Jul 23, 2026 release

Highlights • Q2 sales grew 13.6% to $1.74 billion 1 , constant currency 2 sales grew 12.5% • Q2 TAVR sales grew 11.3% to $1.26 billion 1 ; constant currency 2 sales grew 10.5% • Q2 TMTT sales were $195.9 million 1,3 , driven by portfolio of repair and replacement therapies • Q2 EPS of $0.42 1 ; adjusted 2 EPS of $0.78 1 • Recent clinical data at New York Valves reinforce best-in-class SAPIEN performance and durability; PASCAL, EVOQUE and SAPIEN M3 differentiated body of clinical evidence continues to expand 2026 Outlook • Increasing total company constant currency 2 sales growth guidance: 10% to 11% from 9% to 11% • Increasing TAVR constant currency 2 sales growth guidance: 8% to 9% from 7% to 9% • Increasing TMTT sales guidance: $760 to $780 million from $740 to $780 million • Reaffirming adjusted EPS guidance of $2.95 to $3.05, growing 17% at midpoint • Expected clinical presentations at TCT: PROGRESS and CLASP IITR • Expected Q4 approvals of PASCAL tricuspid indication in U.S. and next-generation PASCAL with Capture Clarity in U.S. and Europe “We delivered stronger-than-expected second quarter sales growth of 12.5%. As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio and agile execution, with growth supported by therapies across TAVR, mitral, tricuspid and surgical, as well as meaningful contributions from each of the regions,” said Bernard Zovighian, Edwards’ CEO. “Today, our company profile has evolved to include multiple strategic platforms across multiple regions that will support durable growth, which gives us confidence in our target of approximately 10% total company sales growth, on average, over the longer term. Our strategic focus coupled with our commitment to early innovation enables us to deliver meaningful impact for patients worldwide.” Transcatheter Aortic Valve Replacement (TAVR) In the se